|
|
xiii | |
Biography |
|
xvii | |
Acknowledgments |
|
xix | |
|
Section I Background and Overview of Diet and GI Tract Health |
|
|
|
1 Plant Family, Carvacrol, and Putative Protection in Gastric Cancer |
|
|
|
|
|
|
1 Plant Family and Phytochemicals |
|
|
3 | (1) |
|
1.1 General Properties of Dietary Phytochemicals |
|
|
3 | (1) |
|
1.2 Classification of Phytochemicals |
|
|
3 | (1) |
|
1.3 Mechanisms of Phytochemicals in Cancer Chemoprevention |
|
|
3 | (1) |
|
|
4 | (5) |
|
2.1 Carvacrol as a Molecule |
|
|
4 | (1) |
|
|
4 | (1) |
|
2.3 Chemical and Physical Properties of Carvacrol |
|
|
5 | (1) |
|
2.4 Metabolism and Excretion of Carvacrol |
|
|
5 | (1) |
|
2.5 Acute Toxicity of Carvacrol |
|
|
5 | (1) |
|
2.6 Biological Activities of Carvacrol |
|
|
5 | (4) |
|
3 Dietary Phytochemicals in Gastric Cancer Chemoprevention |
|
|
9 | (1) |
|
|
10 | (9) |
|
4.1 Anatomy and Physiology |
|
|
10 | (1) |
|
4.2 Epidemiology of Gastric Cancer |
|
|
10 | (1) |
|
4.3 Etiology of Gastric Cancer |
|
|
10 | (1) |
|
4.4 Pathology of Gastric Cancer |
|
|
11 | (1) |
|
4.5 Types of Gastric Cancer |
|
|
11 | (1) |
|
4.6 Stages of Gastric Cancer |
|
|
12 | (1) |
|
|
13 | (1) |
|
4.8 Diagnosis of Gastric Cancer |
|
|
13 | (1) |
|
|
13 | (1) |
|
|
14 | (5) |
|
2 The Physics of Fiber in the Gastrointestinal Tract: Laxation, Antidiarrheal, and Irritable Bowel Syndrome |
|
|
|
|
|
19 | (1) |
|
2 Chronic Idiopathic Constipation |
|
|
20 | (4) |
|
2.1 Most Fibers Have No Laxative Effect, and at Least Four Can Be Constipating |
|
|
20 | (1) |
|
2.2 Insoluble Fiber/Wheat Bran and Laxation |
|
|
20 | (1) |
|
2.3 Soluble Gel-Forming Fiber/Psyllium and Laxation |
|
|
21 | (1) |
|
2.4 Misconceptions About Fiber and Laxation |
|
|
21 | (1) |
|
2.5 Summary: Fiber and Laxation |
|
|
22 | (2) |
|
3 Antidiarrheal Effects of Fiber |
|
|
24 | (2) |
|
3.1 Fermented Fibers/Prebiotics and Treatment/Prevention of Diarrhea |
|
|
24 | (1) |
|
3.2 Prebiotics: Traveler's Diarrhea, Antibiotic-Associated Diarrhea, and Clostridium difficile-Associated Diarrhea |
|
|
24 | (1) |
|
3.3 Fermented Fibers/Prebiotics and Enteral Nutrition-Induced Diarrhea |
|
|
24 | (1) |
|
3.4 Mixed Fibers and Enteral Nutrition-Induced Diarrhea |
|
|
25 | (1) |
|
3.5 Gel-Forming Fibers and Treatment/Prevention of Diarrhea |
|
|
25 | (1) |
|
4 Fiber and Irritable Bowel Syndrome |
|
|
26 | (2) |
|
4.1 Fermentable Fiber/Prebiotics and Irritable Bowel Syndrome |
|
|
26 | (1) |
|
4.2 Insoluble Wheat Bran and Irritable Bowel Syndrome |
|
|
26 | (1) |
|
4.3 Guar Gum and Irritable Bowel Syndrome |
|
|
27 | (1) |
|
4.4 Calcium Polycarbophil and Irritable Bowel Syndrome |
|
|
27 | (1) |
|
4.5 Psyllium and Irritable Bowel Syndrome |
|
|
27 | (1) |
|
4.6 Summary: Fiber and Irritable Bowel Syndrome |
|
|
28 | (1) |
|
4.7 Recommendation to Begin Fiber Therapy Gradually |
|
|
28 | (1) |
|
5 Overall Conclusions for Fiber and Laxation, Antidiarrheal, and Irritable Bowel Syndrome |
|
|
28 | (5) |
|
|
28 | (5) |
|
3 Dietary Interventions and Inflammatory Bowel Disease |
|
|
|
|
|
|
33 | (1) |
|
1.1 Clinical Manifestations and Complications of Inflammatory Bowel Disease |
|
|
33 | (1) |
|
2 Nutritional Issues/Common Problems in Inflammatory Bowel Disease |
|
|
34 | (1) |
|
2.1 Vitamin D Deficiency in Inflammatory Bowel Disease |
|
|
34 | (1) |
|
2.2 Anemia in Inflammatory Bowel Disease |
|
|
34 | (1) |
|
|
35 | (1) |
|
4 Nutritional Interventions in Inflammatory Bowel Disease |
|
|
35 | (1) |
|
5 Some Popular Dietary Intervention in Inflammatory Bowel Disease |
|
|
35 | (3) |
|
5.1 Enteral Nutrition in Inflammatory Bowel Disease |
|
|
35 | (2) |
|
5.2 Dietary Recommendations in Practice |
|
|
37 | (1) |
|
|
38 | (5) |
|
|
38 | (5) |
|
4 The Gastrointestinal System and Obesity |
|
|
|
|
|
|
43 | (1) |
|
1.1 Obesity: Definition, Epidemiology, and Pathophysiology |
|
|
43 | (1) |
|
2 Gastrointestinal Regulation of Food Intake |
|
|
43 | (6) |
|
2.1 The Gastrointestinal Tract in Regulation of Food Intake and Regulation of Energy Balance |
|
|
45 | (4) |
|
3 Complication of Obesity in Gastrointestinal Tract |
|
|
49 | (5) |
|
|
49 | (2) |
|
|
51 | (1) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
4 Treatment of Obesity Focused in the Gastrointestinal Tract |
|
|
54 | (3) |
|
|
55 | (1) |
|
|
55 | (1) |
|
|
56 | (1) |
|
|
57 | (6) |
|
|
57 | (1) |
|
|
57 | (6) |
|
5 Constipation: A Symptom of Chronic Food Intolerance? |
|
|
|
|
|
|
|
|
63 | (1) |
|
|
63 | (2) |
|
|
63 | (1) |
|
|
63 | (1) |
|
|
64 | (1) |
|
|
64 | (1) |
|
2.5 Current Management Practices |
|
|
64 | (1) |
|
3 Emerging Views of Pediatric Chronic Constipation |
|
|
65 | (3) |
|
3.1 The Nuclear Colonic Transit Study |
|
|
65 | (2) |
|
3.2 Colonic Dysmotility Subtypes |
|
|
67 | (1) |
|
3.3 Slow-Transit Constipation |
|
|
67 | (1) |
|
3.4 Rapid-Transit Constipation |
|
|
68 | (1) |
|
4 Adverse Food Reactions and Chronic Constipation |
|
|
68 | (3) |
|
4.1 Adverse Food Reactions |
|
|
68 | (1) |
|
4.2 Adverse Food Reactions (AFR's) and Chronic Constipation |
|
|
69 | (1) |
|
4.3 Exclusion Diet as a Management Strategy for Chronic Constipation |
|
|
70 | (1) |
|
|
71 | (2) |
|
|
71 | (2) |
|
6 Food, Nutrients, and Dietary Supplements in Management of Disorders of Gut-Brain Interaction, Formerly Functional Gastrointestinal Disorders |
|
|
|
|
|
|
73 | (1) |
|
2 Reflux Hypersensitivity and Functional Heartburn |
|
|
74 | (1) |
|
|
75 | (1) |
|
4 Irritable Bowel Syndrome and Functional Constipation |
|
|
76 | (2) |
|
|
78 | (3) |
|
|
79 | (2) |
|
7 Vitamin D and Quality of Life of Patients With Irritable Bowel Syndrome |
|
|
|
|
|
|
81 | (1) |
|
2 Health-Related Quality of Life of Irritable Bowel Syndrome Patients |
|
|
81 | (2) |
|
|
83 | (1) |
|
4 Vitamin D Deficiency in Irritable Bowel Syndrome |
|
|
83 | (1) |
|
5 Vitamin D and Quality of Life in Irritable Bowel Syndrome |
|
|
83 | (2) |
|
|
85 | (1) |
|
7 Conclusions 86 List of Abbreviations 86 References |
|
|
86 | (5) |
|
Section II Nutrition and GI Tract |
|
|
|
8 Sealing the Leaky Gut Represents a Beneficial Mechanism of Zinc Intervention for Alcoholic Liver Disease |
|
|
|
|
|
|
91 | (1) |
|
2 Gut Barrier Dysfunction in the Development of Alcoholic Liver Disease |
|
|
92 | (2) |
|
2.1 Alcohol-Induced Cut Hyperpermeability |
|
|
92 | (1) |
|
2.2 Bacterial Translocation and Hepatic Signaling in Alcoholic Liver Disease |
|
|
93 | (1) |
|
3 Zinc Metabolism and Function |
|
|
94 | (1) |
|
3.1 Physiological Functions of Zinc |
|
|
94 | (1) |
|
3.2 Regulation of Zinc Homeostasis |
|
|
94 | (1) |
|
4 Zinc Deficiency in Alcoholic Liver Disease |
|
|
95 | (3) |
|
4.1 Occurrence of Zinc Deficiency in Alcoholic Liver Disease |
|
|
95 | (1) |
|
4.2 Mechanisms of Alcohol-Induced Zinc Deficiency |
|
|
96 | (1) |
|
4.3 Effects of Zinc Deficiency on the Liver |
|
|
97 | (1) |
|
4.4 Effects of Zinc Deficiency on the Gut Barrier |
|
|
97 | (1) |
|
5 Zinc Intervention for Alcoholic Liver Disease |
|
|
98 | (2) |
|
5.1 Dietary Zinc Supplementation Prevents Alcohol-Induced Endotoxemia and Intestinal Barrier Dysfunction |
|
|
99 | (1) |
|
5.2 Dietary Zinc Supplementation Restores the Function of Intestinal HNF-4α |
|
|
100 | (1) |
|
5.3 Dietary Zinc Supplementation Reduces Endotoxin Levels in the Intestinal Lumen |
|
|
100 | (1) |
|
|
100 | (7) |
|
|
101 | (6) |
|
9 Exclusive Enteral Nutrition in Children With Crohn's Disease: A Focused Nutritional Intervention |
|
|
|
|
|
107 | (1) |
|
|
107 | (1) |
|
3 Nutritional Impact of Chron's Disease in Children |
|
|
108 | (1) |
|
4 Exclusive Enteral Nutrition |
|
|
109 | (2) |
|
4.1 Typical Exclusive Enteral Nutrition Protocol |
|
|
109 | (1) |
|
4.2 Exclusive Enteral Nutrition and Induction of Remission |
|
|
109 | (1) |
|
4.3 Other Benefits of Exclusive Enteral Nutrition |
|
|
109 | (1) |
|
4.4 Adverse Effects of Exclusive Enteral Nutrition |
|
|
110 | (1) |
|
4.5 EEN for Complicated CD |
|
|
110 | (1) |
|
4.6 Maintenance EN to Maintain Remission/Prevent Relapse |
|
|
110 | (1) |
|
5 Mechanisms of Action of Exclusive Enteral Nutrition |
|
|
111 | (1) |
|
5.1 Putative Mechanisms of Action of Exclusive Enteral Nutrition |
|
|
111 | (1) |
|
5.2 Exclusive Enteral Nutrition and the Intestinal Microbiota |
|
|
111 | (1) |
|
5.3 EEN Has Direct Antiinflammatory Effects and Enhances Barrier Function in Epithelial Cells |
|
|
111 | (1) |
|
|
112 | (5) |
|
|
113 | (4) |
|
10 Gut Microbes in Liver Diseases: Dietary Intervention for Promoting Hepatic Health |
|
|
|
|
|
|
|
117 | (1) |
|
|
117 | (2) |
|
|
118 | (1) |
|
|
118 | (1) |
|
3 Gut Microbiota and Liver |
|
|
119 | (2) |
|
3.1 Liver as Vascular Sentinel of the Immune System |
|
|
119 | (1) |
|
|
120 | (1) |
|
3.3 Factors Affecting the Gut Microbiota in Liver Disease |
|
|
120 | (1) |
|
4 Liver Diseases and Role of Gut Microbiota |
|
|
121 | (2) |
|
4.1 Nonalcoholic Fatty Liver Disease |
|
|
121 | (1) |
|
4.2 Alcoholic Fatty Liver Disease |
|
|
122 | (1) |
|
|
122 | (1) |
|
4.4 Hepatic Encephalopathy |
|
|
122 | (1) |
|
|
122 | (1) |
|
4.6 Hepatocellular Carcinoma |
|
|
123 | (1) |
|
|
123 | (1) |
|
4.8 Inflammatory Bowel Diseases |
|
|
123 | (1) |
|
5 Dietary Intervention Strategies for Liver Diseases |
|
|
123 | (3) |
|
|
124 | (1) |
|
5.2 Probiotic-Based Intervention for Promoting Hepatic Health |
|
|
124 | (1) |
|
|
125 | (1) |
|
|
126 | (9) |
|
|
126 | (9) |
|
|
127 | (1) |
|
|
127 | (8) |
|
Section III Probiotics, Prebiotics, Symbiotics in Intestinal Functions |
|
|
|
11 Feasible Options to Control Colonization of Enteric Pathogens With Designed Synbiotics |
|
|
|
|
|
|
|
|
|
|
135 | (1) |
|
2 Probiotics and Its Role in the Prevention of Enteric Pathogen Colonization |
|
|
136 | (2) |
|
2.1 Environment of the Gut Flora |
|
|
136 | (1) |
|
2.2 Interaction Between Probiotics and Intestinal Epithelial Barrier |
|
|
137 | (1) |
|
2.3 Strengthening of the Epithelial Barrier |
|
|
138 | (1) |
|
2.4 Application of Probiotics in Prevention of Enteric Bacterial Infections |
|
|
138 | (1) |
|
3 Probiotics and Its Antimicrobial Role in Reduction of Enteric Bacterial Pathogen Growth |
|
|
138 | (2) |
|
3.1 Probiotics Producing Antimicrobial Substances |
|
|
139 | (1) |
|
3.2 Antimicrobial Action by Probiotics |
|
|
139 | (1) |
|
3.3 Antimicrobial Activity of Probiotics in Food Products |
|
|
140 | (1) |
|
4 Combined Effect of Pre- and Probiotic and Its Limitation |
|
|
140 | (3) |
|
4.1 The Combined Effects in Form of Synbiotics |
|
|
141 | (1) |
|
4.2 Mechanisms of Synbiotics in Preventing Enteric Diseases |
|
|
141 | (1) |
|
4.3 The Double Inhibitory Actions by Synbiotics |
|
|
142 | (1) |
|
4.4 Limitations of Synbiotics Application |
|
|
142 | (1) |
|
5 Feasible Alternative to Overcome the Limitation of Symbiotic |
|
|
143 | (1) |
|
5.1 Alternative Functional Ingredients to Probiotics |
|
|
143 | (1) |
|
5.2 Limitation in Prebiotics and Potential Solutions |
|
|
144 | (1) |
|
5.3 Antimicrobials' Potential in Combinational Alternatives |
|
|
144 | (1) |
|
|
144 | (7) |
|
|
145 | (1) |
|
|
145 | (6) |
|
12 The Role of Prebiotics in Disease Prevention and Health Promotion |
|
|
|
|
|
|
|
|
|
|
151 | (1) |
|
2 Modulation of Gut Microbiota |
|
|
152 | (1) |
|
3 Prebiotics Effects in Human Health |
|
|
153 | (5) |
|
3.1 Production of Short-Chain Fatty Acids |
|
|
153 | (1) |
|
|
154 | (1) |
|
3.3 Inflammatory Bowel Disease |
|
|
155 | (1) |
|
3.4 Cardiovascular Disease |
|
|
156 | (1) |
|
3.5 Type II Diabetes and Glycemic Control |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
158 | (1) |
|
|
158 | (3) |
|
5 Insight Into Prebiotics Effect on the Growth of Harmful Bacteria |
|
|
161 | (2) |
|
6 Conclusions and Future Directions |
|
|
163 | (6) |
|
|
163 | (1) |
|
|
163 | (6) |
|
13 Probiotics From Food Products and Gastrointestinal Health |
|
|
|
|
|
|
|
169 | (1) |
|
|
169 | (1) |
|
3 Mechanisms of Action of Probiotics |
|
|
170 | (1) |
|
3.1 Antimicrobial Effects |
|
|
170 | (1) |
|
3.2 Enhancement of Mucosal Barrier Integrity |
|
|
171 | (1) |
|
|
171 | (1) |
|
4 Dietary Interventions of Probiotics in Gastrointestinal Disorders |
|
|
171 | (1) |
|
5 Probiotic Functional Foods, Status, and Claims |
|
|
172 | (1) |
|
|
173 | (6) |
|
|
173 | (1) |
|
|
174 | (5) |
|
14 Prebiotics for Gastrointestinal Infections and Acute Diarrhea |
|
|
|
|
Maria Jose Rodriguez-Lagunas |
|
|
|
|
|
179 | (1) |
|
2 Gastrointestinal Infections |
|
|
179 | (2) |
|
3 Prebiotics: Types and Mechanisms of Action |
|
|
181 | (2) |
|
3.1 Definition and Types of Prebiotics |
|
|
181 | (1) |
|
3.2 Mechanisms of Action in the Protection of Gastrointestinal Infections |
|
|
181 | (1) |
|
3.3 Microbiota-Dependent Mechanisms |
|
|
181 | (2) |
|
3.4 Microbiota-Independent Mechanisms |
|
|
183 | (1) |
|
4 Prebiotics in Gastrointestinal Diseases |
|
|
183 | (4) |
|
|
183 | (1) |
|
4.2 Evidences in Animal Models of Infection |
|
|
183 | (3) |
|
4.3 Prebiotics in Human Infections of the Gastrointestinal Tract |
|
|
186 | (1) |
|
|
187 | (6) |
|
|
187 | (1) |
|
|
188 | (5) |
|
15 Probiotics and Applications to Constipation |
|
|
|
|
|
|
1 The Role of Microbiota in Gut Motility |
|
|
193 | (1) |
|
2 Gut Microbiota and Gastrointestinal Health |
|
|
193 | (1) |
|
3 Microbiota Alterations in Functional Constipation |
|
|
194 | (1) |
|
4 Probiotics in the Management of Functional Constipation |
|
|
194 | (1) |
|
|
195 | (2) |
|
|
195 | (2) |
|
16 New Functional Properties of Fermented Rice Bran in Food Processing and Inflammatory Bowel Disease Model Mice |
|
|
|
|
|
197 | (1) |
|
2 Preparation of Fermented Rice Bran for Ammonia Reduction in Shark Meat |
|
|
198 | (1) |
|
3 Effect of Fermented Rice Bran on Ammonia Content and Preference Ranking in Shark and Other Fish Meat |
|
|
199 | (1) |
|
4 Dietary and Lifestyle Disease Indices and Cecal Microbiota in High-Fat Diet, Dietary Fiber-Free Diet, or DSS-Induced IBD Models in Closed Colony Mice |
|
|
199 | (1) |
|
5 Protective Effects of FRB in DSS-Induced IBD Model ICR Mice |
|
|
200 | (4) |
|
5.1 Total Phenolic Content and Antioxidant Properties |
|
|
201 | (1) |
|
5.2 Immune Promotion and Antiinflammation Activity in Murine Macrophage RAW264.7 Cells |
|
|
201 | (2) |
|
5.3 Protective Effects of FRB-AES in DSS-Induced IBD Model ICR Mice |
|
|
203 | (1) |
|
|
204 | (5) |
|
|
204 | (1) |
|
|
204 | (2) |
|
|
206 | (3) |
|
Section IV Microbes and GI Tract |
|
|
|
17 Zataria multiflora and Gastrointestinal Tract Disorders |
|
|
|
|
|
209 | (1) |
|
2 Beneficial Effects of ZM on Different Gastrointestinal Tract Diseases |
|
|
210 | (3) |
|
2.1 Stomatitis and Intraoral Ulcers |
|
|
210 | (1) |
|
2.2 Gastric or Duodenal Ulcers |
|
|
210 | (1) |
|
2.3 Irritable Bowel Syndrome and Inflammatory Bowel Disease |
|
|
210 | (1) |
|
2.4 Intestinal Infections |
|
|
211 | (1) |
|
2.5 Colon Cancer Chemopreventive Effect |
|
|
211 | (1) |
|
2.6 Hepatoprotective Effects |
|
|
211 | (1) |
|
2.7 Road Mapping for Future Studies and Conclusion |
|
|
211 | (1) |
|
|
212 | (1) |
|
18 Influence of a Cocoa-Enriched Diet on the Intestinal Immune System and Microbiota |
|
|
|
|
|
|
|
|
213 | (1) |
|
|
213 | (1) |
|
3 Cocoa and Gut Microbiota |
|
|
214 | (3) |
|
3.1 Role of Cocoa Flavonoids on Cocoa Microbiota Influence |
|
|
215 | (1) |
|
3.2 Cocoa Fiber and Microbiota |
|
|
216 | (1) |
|
3.3 Cocoa Theobromine and Microbiota |
|
|
216 | (1) |
|
4 Cocoa and the Intestinal Immune System |
|
|
217 | (2) |
|
4.1 Cocoa and the Intestinal Epithelium |
|
|
217 | (1) |
|
4.2 Cocoa and the Intestinal immunoglobulin A |
|
|
217 | (1) |
|
4.3 Cocoa and Gut-Associated Lymphoid Tissue Populations |
|
|
218 | (1) |
|
5 Cocoa in Gastrointestinal Disease and Food Hypersensitivity |
|
|
219 | (2) |
|
5.1 Influence of Cocoa intake in Intestinal Inflammation |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
221 | (8) |
|
|
222 | (7) |
|
|
222 | (7) |
|
Section V Foods and Macro Dietary Materials in GI Function |
|
|
|
19 High-Fiber Diets in Gastrointestinal Tract Diseases |
|
|
|
Ana Leticia Malheiros Silveira |
|
|
Adaliene Versiani Matos Ferreira |
|
|
|
1 Basic Concepts: Dietary Fiber |
|
|
229 | (1) |
|
2 Gastrointestinal Tract and Microbiota Interaction |
|
|
230 | (1) |
|
|
231 | (1) |
|
3.1 High-Fiber Diet in Gastritis |
|
|
231 | (1) |
|
4 Inflammatory Bowel Disease |
|
|
232 | (6) |
|
4.1 Microbiota and Inflammatory Bowel Disease |
|
|
232 | (1) |
|
4.2 Dietary Fiber in Inflammatory Bowel Disease |
|
|
233 | (5) |
|
|
238 | (1) |
|
5.1 Microbiota and Mucositis |
|
|
239 | (1) |
|
5.2 Dietary Fiber in Mucositis |
|
|
239 | (1) |
|
|
239 | (6) |
|
|
240 | (5) |
|
20 Dietary Interventions in Fatty Liver |
|
|
|
|
|
|
245 | (1) |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
5 Probiotics, Prebiotics, and Synbiotics |
|
|
246 | (1) |
|
6 Seal Oil (N-3 Polyunsaturated Fatty Acids) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
250 | (7) |
|
|
250 | (7) |
|
21 Rice Bran Usage in Diarrhea |
|
|
|
|
|
1 Overall Health Benefits of Rice Bran Dietary Supplement |
|
|
257 | (1) |
|
2 Dietary Rice Bran Supplementation in Reducing Diarrhea |
|
|
257 | (2) |
|
2.1 Diarrhea in Irritable Bowel Syndrome |
|
|
257 | (1) |
|
2.2 Human Rotavirus-Induced Diarrhea |
|
|
258 | (1) |
|
2.3 Human Noroviruses-Induced Diarrhea |
|
|
259 | (1) |
|
3 Mechanisms for Rice Bran Usage in Reducing Diarrhea |
|
|
259 | (2) |
|
3.1 Antimicrobial and Antiviral Activities |
|
|
260 | (1) |
|
3.2 Prebiotic and Microbiota Modulatory Properties |
|
|
260 | (1) |
|
3.3 Effects on Intestinal Immunity and Overall Health |
|
|
260 | (1) |
|
|
261 | (4) |
|
|
261 | (4) |
|
22 Milk Bacteria and Gastrointestinal Tract: Microbial Composition of Milk |
|
|
|
|
|
|
265 | (1) |
|
2 Sources of Milk Organisms |
|
|
265 | (1) |
|
3 Contamination in the Mammary Glands |
|
|
265 | (1) |
|
4 Contamination Sources in the External Environment |
|
|
265 | (1) |
|
5 Contamination From Handling and Storage Equipment |
|
|
266 | (1) |
|
6 Microbial Composition of Milk From Different Sources |
|
|
266 | (2) |
|
|
266 | (1) |
|
|
267 | (1) |
|
|
267 | (1) |
|
|
267 | (1) |
|
|
267 | (1) |
|
7 Important Microorganisms Found in Raw Milk |
|
|
268 | (2) |
|
|
268 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
7.8 Gram-Positive Subpopulations |
|
|
270 | (1) |
|
7.9 Gram-Negative Subpopulations |
|
|
270 | (1) |
|
|
270 | (1) |
|
|
270 | (1) |
|
8 Impact of Storage Conditions and Treatments |
|
|
270 | (2) |
|
|
270 | (1) |
|
|
271 | (1) |
|
|
271 | (1) |
|
9 Biopreservative Potential of Raw Milk Microorganisms |
|
|
272 | (1) |
|
10 Human Health Association |
|
|
272 | (1) |
|
11 Pathogenic Bacteria Found in Milk |
|
|
272 | (1) |
|
11.1 Listeria monocytogenes |
|
|
272 | (1) |
|
11.2 Staphylococcus aureus |
|
|
272 | (1) |
|
|
272 | (1) |
|
|
273 | (1) |
|
|
273 | (1) |
|
|
273 | (1) |
|
|
273 | (1) |
|
|
273 | (1) |
|
12 Health-Promoting Bacteria |
|
|
273 | (1) |
|
|
273 | (4) |
|
|
274 | (1) |
|
|
274 | (3) |
|
23 Polyphenols in the Prevention of Ulcerative Colitis: A Revisit |
|
|
|
|
|
|
|
|
|
|
|
Manjeshwar Shrinath Baliga |
|
|
|
277 | (1) |
|
2 Curcumin, the Active Component of Turmeric |
|
|
277 | (1) |
|
|
278 | (1) |
|
|
279 | (1) |
|
|
279 | (1) |
|
|
279 | (1) |
|
|
280 | (1) |
|
8 Green Tea Polyphenols in Colitis |
|
|
280 | (2) |
|
|
282 | (1) |
|
|
282 | (1) |
|
|
282 | (2) |
|
|
284 | (1) |
|
|
284 | (1) |
List of Abbreviations |
|
284 | (1) |
References |
|
285 | (4) |
Index |
|
289 | |